Sequence information
DRAVP ID DRAVPc033
Name Ansuvimab
Sequence
Molecular Formula Not Available
Condition/Disease Zaire ebolavirus infection
Group Approved
Type Antibody
Description Ansuvimab is a fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Active sequence/Structure
External Links
DrugBank Accession Number DB16385
Pubchem ID 433770931
CHEMBL ID CHEMBL4594388
UNII TG8IQ19NG2
CAS 2375952-29-5
ClinicalTrails Information
NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
---|---|---|---|---|---|
NCT05067166 | Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP | Hemorrhagic Fever, Ebola | Available | Not Available | Ridgeback Biotherapeutics, LP |
NCT04822376 | Prophylaxis Vaccine Antibodies Ebola (PROVAE) | Ebolavirus Disease Prevention | Not yet recruiting | Phase 2 | ANRS, Emerging Infectious Diseases |